Sun Pharma

What is USFDA's Form 483?

The US carries out regular inspections at offshore drug making units to ensure quality compliance. In a recent check, the US FDA has issued Form 483 to Sun Pharma Halol unit. Let's demystify Form 483

Claims drug has a new mechanism of action compared to currently available lipid lowering agents, is indicated for people with inherited genetic disorder

The last two years saw limited physical inspections due to travel restrictions during the pandemic

Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days

Business Standard brings you the top headlines on Tuesday

In the past five days, the stock has fallen over 5 per cent. In comparison, the S&P BSE Sensex declined 3.75 per cent during the same period

Leading drug firms Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products in the US market for various reasons

The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.

Sun Pharma said has disputed the claims of the plaintiffs and defended these matters vigorously

CLOSING BELL: Tech M, Tata Motors, BPCL, ITC, JSW Steel, PowerGrid, Bajaj Auto, Infosys, TCS, Bajaj Finserv, Bharti Airtel, Wipro and IndusInd Bank were the other gainers

Sun Pharma said it will pay Rs 5.32 crore for the stake

Among individual stocks, Aurobindo Pharma was the top gainer, which rallied 8 per cent to Rs 688.90 on the BSE in intra-day trade.

Rerating on the cards; the domestic business is expected to outperform

The technical analyst expects the Nifty to turn bearish below 16,555; whereas on the upside sees resistance around 16,927 and 17,040 levels.

CLOSING BELL: Ukrainian President Volodymyr Zelenskyy's reported statement that his country has cooled down on the question of a NATO membership calmed investor nerves

MTNL is in focus as the Centre is considering relaxing some norms that led to the failure in attracting bids for assets of BSNL and MTNL as they look to restart the auction for their non-core assets.

Sun Pharma the biggest gainer among Sensex firms with a jump of 3.99 per cent, followed by TCS, NTPC, Wipro, Tech Mahindra, Dr Reddy's, UltraTech Cement and Infosys

Shares of Adani Power are likely to be in focus as the company received a favourable verdict from the Supreme Court against power discoms in Rajasthan.

Leading homegrown drug makers Aurobindo Pharma and Sun Pharmaceutical Industries are recalling different products in the US market due to deviation from standard manufacturing norms.

'As India becomes an increasingly more important component for the global supply chain, that should benefit the industry going forward,' Sun Pharma Managing Director Dilip Shanghvi said